{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:06:45Z","timestamp":1790662005949,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003594.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000}}],"reference-count":180,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003594.pub7","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T07:21:21Z","timestamp":1746688881000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interventions for idiopathic steroid-resistant nephrotic syndrome in children"],"prefix":"10.1002","volume":"2025","author":[{"given":"Isaac D","family":"Liu","sequence":"additional","affiliation":[{"name":"Duke-NUS Medical School; Yong Loo Lin School of Medicine; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narelle S","family":"Willis","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"College of Medicine and Public Health; Flinders University; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M","family":"Hodson","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00467-008-0794-1","article-title":"Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie","volume":"23","author":"Plank","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00467-003-1314-y","article-title":"Enalapril dosage in steroid-resistant nephrotic syndrome","volume":"19","author":"Bagga","year":"2004","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0003|cit3","unstructured":"Bagga A Mudigoudar BD Vasudev V Hari P Low (LD) versus high dose (HD) enalapril therapy in steroid resistant nephrotic syndrome (SRNS) [abstract] 7th Asian Congress of Pediatric Nephrology; 2000 Nov 4-6; Singapore 2000"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0004|cit4","first-page":"190","article-title":"Comparison of pulse methyl prednisolone vs cyclosporin based therapy in steroid resistant focal segmental glomerulosclerosis [abstract]","volume":"12","author":"Bhaumik","year":"2002","journal-title":"Indian Journal of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0005|cit5","first-page":"S122","article-title":"Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome","volume":"82 Suppl 1","author":"Chongviriyaphan","year":"1999","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0006|cit6","first-page":"1480","article-title":"Randomized controlled trial (RCT) on efficacy and safety of cyclosporin (CyA) vs tacrolimus (Tac) in steroid resistant nephrotic syndrome (SRNS) [CRG030600042] [abstract no: 182 (OP)]","volume":"22","author":"Choudhry","year":"2007","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub7-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial","volume":"53","author":"Choudhry","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003594.pub7-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"iii97","DOI":"10.1093\/ndt\/gfx134.TO042","article-title":"Antiproteinuric effect of sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, in patients with primary focal segmental glomerulosclerosis (FSGS): a subgroup analysis of the DUET trial [abstract no: TO042]","volume":"32","author":"Gesualdo","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.20203110S155b","article-title":"Complete remission of proteinuria in patients with focal segmental glomerulosclerosis treated with sparsentan, a dual endothelin and angiotensin receptor antagonist, in the DUET trial [abstract]","volume":"31","author":"Hogan","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0010|cit10","first-page":"61","article-title":"Long-term effects of sparsentan, a dual angiotensin and endothelin receptor antagonist in primary focal segmental glomerulosclerosis (FSGS): interim 84-week analysis of the DUET trial [abstract no: FR-OR087]","volume":"29","author":"Hogan","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0011|cit11","first-page":"843","article-title":"Sparsentan pharmacokinetics and pharmacodynamics as the basis of dose selection for primary focal segmental glomerular sclerosis (FSGS) [abstract no: SA-PO635]","volume":"28","author":"Karol","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ekir.2017.02.019","article-title":"Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET)","volume":"2","author":"Komers","year":"2017","journal-title":"Kidney International Reports"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0013|cit13","first-page":"2025","article-title":"DUET pediatric subset: a phase 2 study evaluating sparsentan in focal segmental glomerulosclerosis (FSGS) [abstract no: IPN11173-84]","volume":"34","author":"Lieberman","year":"2019","journal-title":"Pediatric Nephrology"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.ekir.2019.05.432","article-title":"No impact of newly initiated immunosuppressive therapy observed on long-term antiproteinuric effect of sparsentan in focal segmental glomerulosclerosis: interim 84-week analysis of the DUET trial [abstract no: SUN-037]","volume":"4","author":"Tesar","year":"2019","journal-title":"Kidney International Reports"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.ekir.2023.07.022","article-title":"Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial","volume":"8","author":"Trachtman","year":"2023","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0016|cit16","first-page":"380","article-title":"Impact of sparsentan on quality of life (QOL) in focal segmental glomerulosclerosis (FSGS) patients in DUET: an interim analysis [abstract]","volume":"30","author":"Trachtman","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub7-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0018|cit18","first-page":"2B","article-title":"Efficacy and safety of sparsentan, a dual angiotensin II (Ang II) and endothelin (ET) type A receptor antagonist in patients with focal segmental glomerulosclerosis (FSGS): a phase 2 trial (DUET) [abstract no: HI-OR06]","volume":"27","author":"Trachtman","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003594.pub7-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/ndt\/gfy104.FP129","article-title":"Newly administered immunosuppressive therapy (IST) has no impact on long-term antiproteinuric effect of sparsentan (SPAR), a dual angiotensin and endothelin receptor antagonist, in patients with primary focal segmental glomerulosclerosis (FSGS): interim analysis of the DUET trial [abstract no: FP129]","volume":"33","author":"Trachtman","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0020|cit20","first-page":"44","article-title":"Long-term effect of sparsentan (SPAR), a dual angiotensin and endothelin receptor antagonist, on proteinuria in patients with primary FSGS: interim analysis of the DUET trial [abstract no: FR-OR026]","volume":"28","author":"Trachtman","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0021|cit21","first-page":"379","article-title":"Incremental reduction of proteinuria and kidney survival in FSGS [abstract]","volume":"30","author":"Troost","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2019.12.017","article-title":"Study design of the phase 3 sparsentan vs irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis (FSGS)","volume":"5","author":"Komers","year":"2020","journal-title":"Kidney International Reports"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub7-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.ajkd.2019.03.375","article-title":"Sparsentan for treatment of patients with focal segmental glomerulosclerosis (FSGS): design of the phase 3 DUPLEX study [abstract]","volume":"73","author":"Trachtman","year":"2019","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00868243","article-title":"Intravenous pulse cyclophosphamide - a new regime for steroid-resistant minimal change nephrotic syndrome","volume":"8","author":"Elhence","year":"1994","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0026|cit26","unstructured":"Gupta A Elhence R Kher V Gulati S Sharma RK IV cyclophosphamide - a new regimen for steroid nonresponsive minimal change disease [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 84"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0027|cit27","first-page":"382","article-title":"Implementing a second randomized trial enrolling mid-study treatment failures from the Focal Segmental Glomerular Sclerosis (FSGS) clinical trial [abstract no: 33]","volume":"4","author":"Gassman","year":"2007","journal-title":"Clinical Trials (London, England)"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2215\/CJN.02310508","article-title":"Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group","volume":"4","author":"Joy","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.ajkd.2009.08.019","article-title":"Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group","volume":"55","author":"Joy","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-015-1973-1","article-title":"A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS)","volume":"72","author":"Ternant","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0031|cit31","first-page":"1629","article-title":"Novel therapies in resistant FSGS: preliminary results [abstract no: 879 (P)]","volume":"22","author":"Trachtman","year":"2007","journal-title":"Pediatric Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0032|cit32","first-page":"197a","article-title":"Neutrophil gelatinase-associated lipocalcin (NGAL) and alternate pathway of complement (APC) factors as biomarkers of response to treatment in patients with focal segmental glomerulosclerosis (FSGS) [abstract no: TH-PO368]","volume":"22","author":"Trachtman","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2369-12-8","article-title":"Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design","volume":"12","author":"Trachtman","year":"2011","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-015-0094-5","article-title":"Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the FONT clinical trial group","volume":"16","author":"Trachtman","year":"2015","journal-title":"BMC Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.06100612","article-title":"Association of histologic variants in FSGS clinical trial with presenting features and outcomes","volume":"8","author":"D'Agati","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cts.12003","article-title":"Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT)","volume":"6","author":"Ferris","year":"2013","journal-title":"Clinical & Translational Science"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003594.pub7-BIB0037|cit37","first-page":"559A","article-title":"A preliminary report of the focal segmental glomerulosclerosis clinical trial (FSGS-CT) [abstract no: F-PO1984]","volume":"19","author":"Gassman","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0038|cit38","first-page":"382","article-title":"Implementing a second randomized trial enrolling mid-study treatment failures from the Focal Segmental Glomerular Sclerosis (FSGS) Clinical Trial [abstract no: 33]","volume":"4","author":"Gassman","year":"2007","journal-title":"Clinical Trials"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD003594.pub7-BIB0039|cit39","first-page":"147","article-title":"Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) study cohort [abstract no: TH-PO165]","volume":"20","author":"Gipson","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ki.2010.485","article-title":"Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life","volume":"79","author":"Gipson","year":"2011","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0042|cit42","first-page":"558A","article-title":"Multicenter randomized clinical trial of FSGS in children and young adults [abstract no: F-PO1014]","volume":"16","author":"Greene","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2215\/CJN.08330812","article-title":"Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS","volume":"8","author":"Hogg","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0044|cit44","first-page":"1443","article-title":"Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial","volume":"26","author":"Kopp","year":"2015","journal-title":"Journal of the American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0045|cit45","first-page":"41A","article-title":"APOL1 variant-associated FSGS is more aggressive but manifests similar response to cyclosporine and mycophenolate compared to others forms of primary FSGS [abstract no: FR-OR050]","volume":"23","author":"Kopp","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD003594.pub7-BIB0046|cit46","first-page":"148A","article-title":"Prevalence of blood pressure (BP) control in the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) study cohort [abstract]","volume":"20","author":"Middleton","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0047|cit47","first-page":"417","article-title":"Optimizing logistics under a three level administration system: coordination of the Focal Segmental Glomerular Sclerosis (FSGS) trial [abstract no: P63]","volume":"4","author":"Radeva","year":"2007","journal-title":"Clinical Trials (London, England)"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0048|cit48","first-page":"471","article-title":"Measuring quality of life (QOL) in children and young adults in the focal segmental glomerulosclerosis clinical trial (FSGS-CT) [abstract]","volume":"7","author":"Radeva","year":"2010","journal-title":"Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub7-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00467-015-3146-y","article-title":"Adiponectin in children and young adults with focal segmental glomerulosclerosis","volume":"30","author":"Sethna","year":"2015","journal-title":"Pediatric Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0050|cit50","first-page":"197a","article-title":"Neutrophil gelatinase-associated lipocalcin (NGAL) and alternate pathway of complement (APC) factors as biomarkers of response to treatment in patients with focal segmental glomerulosclerosis (FSGS) [abstract no: TH-PO368]","volume":"22","author":"Trachtman","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD003594.pub7-BIB0051|cit51","first-page":"147A","article-title":"Quality of life in children with focal segmental glomerulosclerosis (FSGS): baseline findings. Report of the FSGS-Clinical Trial (CT) [abstract no: TH-PO164]","volume":"20","author":"Trachtman","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","article-title":"Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis","volume":"77","author":"Troost","year":"2021","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0053|cit53","first-page":"727A","article-title":"Osteopontin (OPN) and transforming growth factor beta 1 (TGFb1) in steroid resistant primary focal segmental glomerulosclerosis (FSGS), FSGS-clinical trial (FSGS-CT) experience [abstract no: SA-PO390]","volume":"23","author":"Woroniecki","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpedi.1988.02150090083029","article-title":"Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study","volume":"142","author":"Garin","year":"1988","journal-title":"American Journal of Diseases of Children"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003594.pub7-BIB0055|cit55","first-page":"1B","article-title":"Multicenter randomized controlled trial comparing efficacy of tacrolimus to intravenous cyclophosphamide in children with steroid resistant nephrotic syndrome [abstract no: LB-OR03]","volume":"22","author":"Gulati","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0056|cit56","first-page":"1803","article-title":"Randomized, multicenter study on tacrolimus & alternate day (AD) prednisolone vs. intravenous (IV) cyclophosphamide & ad prednisolone for steroid resistant nephrotic syndrome (SRNS) [abstract no: 43]","volume":"25","author":"Gulati","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.2012.238","article-title":"Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome","volume":"82","author":"Gulati","year":"2012","journal-title":"Kidney International"},{"issue":"7654","key":"10.1002\/14651858.CD003594.pub7-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(70)91093-7","article-title":"Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children","volume":"1","author":"Abramowicz","year":"1970","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0059|cit59","first-page":"95","article-title":"International trial of azathioprine in nephrotic syndrome in childhood [abstract]","volume":"8","author":"Arneil","year":"1971","journal-title":"Nephron"},{"issue":"7878","key":"10.1002\/14651858.CD003594.pub7-BIB0060|cit60","first-page":"423","article-title":"Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Report of the International Study of Kidney Disease in Children","volume":"2","year":"1974","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub7-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s004670050167","article-title":"Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children","volume":"10","author":"Tarshish","year":"1996","journal-title":"Pediatric Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003594.pub7-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM198003203021214","article-title":"Irreversible renal failure after indomethacin in steroid-resistant nephrosis","volume":"302","author":"Kleinknecht","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0063|cit63","first-page":"96","article-title":"Irreversible renal failure (RF) after indomethacin in steroid resistant nephrosis (SRN) [abstract]","volume":"16","author":"Kleinknecht","year":"1979","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","article-title":"A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children","volume":"7","author":"Lieberman","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003594.pub7-BIB0065|cit65","first-page":"289","article-title":"A randomized placebo (PL) controlled double blind trial of cyclosporine (CSA) in steroid resistant (SR) idiopathic focal segmental glomerulosclerosis (FSGS) in children. A report of the New York, New Jersey Pediatric Nephrology Collaborative Study Group [abstract]","volume":"4","author":"Tejani","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0067|cit67","first-page":"C73","article-title":"Efficacy of IV pulse cyclophosphamide (CP) vs IV steroids and oral CP for steroid resistant nephrotic syndrome [abstract no: OFC44]","volume":"19","author":"Mantan","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00467-008-0860-8","article-title":"Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome","volume":"23","author":"Mantan","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0069|cit69","first-page":"724a","article-title":"Plasmapheresis in steroid-resistant FSGS [abstract no: SA-PO379]","volume":"23","author":"Mattoo","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0070|cit70","first-page":"2150","article-title":"Rituximab plus mycophenolate mofetil versus rituximab plus cyclosporine for treatment of steroid-resistant nephrotic syndrome [abstract no: IPN12007-81]","volume":"34","author":"Mazaheri","year":"2019","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","article-title":"A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome","volume":"43","author":"Ponticelli","year":"1993","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00467-020-04481-y","article-title":"Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial","volume":"35","author":"Ravani","year":"2020","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0073|cit73","first-page":"1879","article-title":"Randomized controlled trial of oral versus intravenous cyclophosphamide in idiopathic steroid resistant nephrotic syndrome [abstract no: 424]","volume":"25","author":"Ohri","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4103\/ijn.IJN_201_16","article-title":"A randomized controlled trial of intravenous versus oral cyclophosphamide in steroid-resistant nephrotic syndrome in children","volume":"27","author":"Shah","year":"2017","journal-title":"Indian Journal of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0075|cit75","first-page":"1600","article-title":"Randomized controlled trial comparing efficacy of mycophenolate mofetil (MMF) & alternate day prednisone versus tacrolimus & prednisolone in maintaining remission in steroid resistant nephrotic syndrome (SRNS) [abstract no: P-SUN200]","volume":"28","author":"Bagga","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0076|cit76","first-page":"B2","article-title":"Randomized trial on efficacy of mycophenolate mofetil versus tacrolimus in maintaining remission in children in steroid resistant nephrotic syndrome [abstract no: HI-OR05]","volume":"26","author":"Sinha","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","article-title":"Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome","volume":"92","author":"Sinha","year":"2017","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0078|cit78","first-page":"774A","article-title":"Superior results with tacrolimus than ciclosporine in children with steroid resistant nephrotic syndrome [abstract no: SA-PO2854]","volume":"22","author":"Medeiros","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0079|cit79","first-page":"1804","article-title":"Efficacy of prednisone-tacrolimus vs. prednisone-cyclosporine in steroid-resistant nephrotic syndrome [abstract no: 47]","volume":"25","author":"Valverde","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nep.12351","article-title":"Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing","volume":"20","author":"Wu","year":"2015","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0081|cit81","unstructured":"Li ZH Yi ZW Clinical study of fosinopril in children with steroid resistant nephrotic syndrome [abstract no: 2344] 23rd International Congress of Paediatrics; 2001 Sep 9-14; Beijing, China 2001"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0082|cit82","first-page":"C114","article-title":"Clinical study of fosinopril in children with steroid resistant nephrotic syndrome [abstract no: P225]","volume":"16","author":"Li","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003594.pub7-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00467-006-0096-4","article-title":"Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome","volume":"21","author":"Yi","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/adc.54.3.204","article-title":"A controlled trial of cyclophosphamide and azathioprine in Nigerian children with the nephrotic syndrome and poorly selective proteinuria","volume":"54","author":"Adeniyi","year":"1979","journal-title":"Archives of Disease in Childhood"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.krcp.2014.05.017","article-title":"Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract]","volume":"33","author":"Ahn","year":"2014","journal-title":"Kidney Research & Clinical Practice"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0086|cit86","first-page":"1361","article-title":"Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract no: 039]","volume":"28","author":"Ahn","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"46","key":"10.1002\/14651858.CD003594.pub7-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0971-4065.34855","article-title":"Randomised controlled study of enalapril in steroid resistant nephrotic syndrome","volume":"12","author":"Arora","year":"2002","journal-title":"Indian Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.24953\/turkjpediatr.2002.2935","article-title":"The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome","volume":"44","author":"Buyukcelik","year":"2002","journal-title":"Turkish Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub7-BIB0090|cit90","first-page":"127-31","article-title":"Exploring the effects of rituximab on nephrotic syndrome","volume":"16","author":"Gaude","year":"2024","journal-title":"International Journal of Pharmaceutical & Clinical Research"},{"issue":"12","key":"10.1002\/14651858.CD003594.pub7-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00467-018-4036-x","article-title":"Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial","volume":"33","author":"Hari","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0092|cit92","first-page":"1737","article-title":"Effect of atorvastatin on lipid profile and carotid intima media thickness (cIMT) in children with refractory nephrotic syndrome: a randomized double blind, placebo controlled trial [abstract no: FP-S14-3]","volume":"31","author":"Hari","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0093|cit93","first-page":"1335","article-title":"Low versus standard dosage of prednisolone for initial treatment of idiopathic nephrotic syndrome in children [abstract no: A0445]","volume":"7","author":"Hiraoka","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1046\/j.1523-1755.2000.00279.x","article-title":"Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children","volume":"58","author":"Hiraoka","year":"2000","journal-title":"Kidney International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003594.pub7-BIB0095|cit95","first-page":"103A","article-title":"Older boys benefit from intensive initial prednisolone therapy for nephrotic syndrome [abstract]","volume":"10","author":"Hiraoka","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub7-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.3390\/biomedicines12112600","article-title":"Rituximab administration to treat nephrotic syndrome in children: 2-year follow-up","volume":"12","author":"Ivanov","year":"2024","journal-title":"Biomedicines"},{"issue":"7","key":"10.1002\/14651858.CD003594.pub7-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00467-006-0054-1","article-title":"Steroid sparing effect of a herbal preparation in steroid-dependent nephrotic syndrome","volume":"21","author":"Iyengar","year":"2006","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0098|cit98","unstructured":"A combination of cyclosporine and prednisolone and a combination of methylprednisolone, cyclosporine and prednisolone for steroid-resistant nephrotic syndrome in children: a randomized controlled study https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000000010"},{"issue":"2 Pt II","key":"10.1002\/14651858.CD003594.pub7-BIB0099|cit99","first-page":"A 33","article-title":"Immunomodulatory treatment in children with steroid-dependent\/steroid-resistant nephrotic syndrome [abstract no: 170]","volume":"20","author":"Jung","year":"1990","journal-title":"European Journal of Clinical Investigation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003594.pub7-BIB0100|cit100","first-page":"524","article-title":"Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria [abstract no: T756-757]","volume":"18","author":"Kano","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5414\/CNP60085","article-title":"Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria","volume":"60","author":"Kano","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003594.pub7-BIB0102|cit102","first-page":"A33","article-title":"Effect of fluvastatin on proteinuria [abstract no: M-PO20068]","volume":"10","author":"Kano","year":"2005","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5414\/CNP63074","article-title":"No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria","volume":"63","author":"Kano","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.22442\/jlumhs.161520465","article-title":"Cyclosporine versus cyclophosphamide in childhood nephrotic syndrome","volume":"15","author":"Khemani","year":"2016","journal-title":"Journal of the Liaquat University of Medical & Health Sciences"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0105|cit105","first-page":"631","article-title":"Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid resistant nephrotic syndrome - a multicenter double-blind comparison study with placebo","volume":"34","author":"Koshikawa","year":"1993","journal-title":"Jin to Toseki [Kidney and Dialysis]"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0106|cit106","first-page":"110","article-title":"Effect of ACE inhibitor and calcium channel blocker on proteinuria in subjects with steroid resistant idiopathic nephrotic syndrome [abstract no: CNO-20]","volume":"11","author":"Kumar","year":"2001","journal-title":"Indian Journal of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0107|cit107","first-page":"454","article-title":"Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome","volume":"52","author":"Kumar","year":"2004","journal-title":"Journal of the Association of Physicians of India"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003594.pub7-BIB0108|cit108","first-page":"569A","article-title":"Therapy of tacrolimus in steroid-resistant minimal-change nephrotic syndrome: a randomized controlled clinical trial [abstract no: F-PO1105]","volume":"17","author":"Li","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0109|cit109","first-page":"1630","article-title":"Equivalent efficacy of HES 130\/0.4 and albumin infusions in children [abstract no: P135]","volume":"23","author":"Pape","year":"2008","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"2279209","DOI":"10.1155\/2022\/2279209","article-title":"Clinical efficacy of Persian medicine diet combined with Western medicine-based diet on proteinuria in pediatric nephrotic syndrome: a randomized controlled clinical trial","volume":"2022","author":"Rahmani","year":"2022","journal-title":"Evidence-Based Complementary & Alternative Medicine: eCAM"},{"issue":"12","key":"10.1002\/14651858.CD003594.pub7-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3724\/SP.J.1008.2011.01340","article-title":"Low-dose tacrolimus combined with tripterygium in treatment of steroid-resistant nephrotic syndrome: a prospective randomized controlled trial","volume":"32","author":"Ren","year":"2011","journal-title":"Academic Journal of Second Military Medical University"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000346256","article-title":"Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial","volume":"37","author":"Ren","year":"2013","journal-title":"American Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub7-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10157-013-0925-2","article-title":"Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial","volume":"18","author":"Saito","year":"2014","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003594.pub7-BIB0114|cit114","first-page":"562A","article-title":"Effect of preprandial once-a-day administration of cyclosporine (CyA) for steroid resistant nephrotic syndrome (SRNS) [abstract no: SA-PO997]","volume":"18","author":"Saito","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub7-BIB0115|cit115","first-page":"634A","article-title":"Benefits of once-a-day preprandial administration and C2 monitoring for the cyclosporine (CyA) treatment of idiopathic membranous nephropathy (IMN) with steroid resistant nephrotic syndrome (SRNS) [abstract no: SA-PO2293]","volume":"20","author":"Saito","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0116|cit116","unstructured":"Saito T Watanabe M Ogahara S Shuto H Kataoka Y Significance of blood concentration of cyclosporine at 2 hours after administration for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: SA285] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10157-016-1340-2","article-title":"Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome","volume":"21","author":"Saito","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003594.pub7-BIB0118|cit118","first-page":"iii430","article-title":"Effects of mizoribin combined with prednisolone for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: Su363]","volume":"3","author":"Saito","year":"2010","journal-title":"NDT Plus"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10157-004-0276-0","article-title":"A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)","volume":"8","author":"Shibasaki","year":"2004","journal-title":"Clinical & Experimental Nephrology"},{"issue":"3 Suppl 4","key":"10.1002\/14651858.CD003594.pub7-BIB0120|cit120","first-page":"262","article-title":"A randomized trial of cyclosporine with low-dose prednisone compared with high-dose prednisone in nephrotic syndrome","volume":"20","author":"Tejani","year":"1988","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0121|cit121","first-page":"96","article-title":"A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children","volume":"59","author":"Tejani","year":"1991","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0122|cit122","first-page":"213","article-title":"Randomized trial of cylosporine and low dose prednisone (P&CS) vs conventional prednisone (P) therapy in recent onset (< 1 yr) nephrotic syndrome (NS) [abstract]","volume":"35","author":"Tejani","year":"1989","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0123|cit123","first-page":"1162","article-title":"Cyclosporin a (Cy-A) treatment in focal and segmental hyalinosis and sclerosis (FSHS): a controlled trial [abstract no: 17]","volume":"36","author":"Walker","year":"1989","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0124|cit124","first-page":"117","article-title":"The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin","volume":"54","author":"Walker","year":"1990","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00431-023-04804-9","article-title":"Single vs split dose of prednisolone in the treatment of relapses of childhood nephrotic syndrome","volume":"182","author":"Weerasooriya","year":"2023","journal-title":"European Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub7-BIB0126|cit126","first-page":"575","article-title":"A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children","volume":"10","author":"Yi","year":"2008","journal-title":"Zhongguo Dangdai Erke Zazhi"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0127|cit127","first-page":"1601","article-title":"Treatment with tacrolimus and prednisone is preferable to intravenous cyclophosphamide for children with difficult-to-treat nephrotic syndrome [abstract no: P-SUN205]","volume":"28","author":"Zhao","year":"2013","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0128|cit128","unstructured":"Efficacy and safety of rituximab to that of calcineurin inhibitors in children with steroid resistant nephrotic syndrome www.clinicaltrials.gov\/ct2\/show\/NCT02382575"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0129|cit129","unstructured":"Availability study of ACTH to treat children SRNS\/SDNS www.ClinicalTrials.gov\/show\/NCT02972346"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub7-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ekir.2017.08.013","article-title":"Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome","volume":"3","author":"Trachtman","year":"2018","journal-title":"Kidney International Reports"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.kint.2016.10.013","article-title":"Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management","volume":"91","author":"Bierzynska","year":"2017","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0132|cit132","unstructured":"Boutron I Page MJ Higgins JPT Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (last updated November 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub7-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2215\/CJN.01190210","article-title":"Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome","volume":"5","author":"B\u00fcscher","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fped.2016.00039","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Frontiers in Pediatrics"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0135|cit135","first-page":"787","volume-title":"Evidence-Based Nephrology","author":"Chua","year":"2009"},{"issue":"21","key":"10.1002\/14651858.CD003594.pub7-BIB0136|cit136","first-page":"1","article-title":"The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review","volume":"11","author":"Colquitt","year":"2007","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ki.2011.191","article-title":"Immunosuppressive treatment of focal and segmental glomerulosclerosis: lessons from a randomized controlled trial","volume":"80","author":"Deegens","year":"2011","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0138|cit138","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (last updated November 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1342\u20138","DOI":"10.1681\/ASN.2013080852","article-title":"Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence","volume":"25","author":"Ding","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/ndt\/gfm092","article-title":"Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated","volume":"22","author":"Ehrich","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00467-011-1851-8","article-title":"Nephrotic syndrome in the Netherlands: a population-based cohort study and a review of the literature","volume":"26","author":"El Bakkali","year":"2011","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00467-005-2097-0","article-title":"Differential risk of remission and ESRD in childhood FSGS","volume":"21","author":"Gipson","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"7650","key":"10.1002\/14651858.CD003594.pub7-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD003594.pub7-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0146|cit146","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0147|cit147","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (last updated November 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00467-024-06468-5","article-title":"In steroid\u2011resistant nephrotic syndrome that meets the strict definition, monogenic variants are less common than expected","volume":"39","author":"Ichikawa","year":"2024","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00467-015-3174-7","article-title":"Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children","volume":"31","author":"Inaba","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub7-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","volume":"35","author":"Trautmann","year":"2020","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3476(81)80760-3","article-title":"The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children","volume":"98","year":"1981","journal-title":"Journal of Pediatrics"},{"issue":"45","key":"10.1002\/14651858.CD003594.pub7-BIB0152|cit152","first-page":"Chapter 4: Neph","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00467-017-3780-7","article-title":"Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options","volume":"33","author":"Kemper","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003594.pub7-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/adc.57.7.544","article-title":"Long-term outcome of primary nephrotic syndrome","volume":"57","author":"Koskimies","year":"1982","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00467-012-2304-8","article-title":"Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ekir.2022.10.030","article-title":"A systematic review and meta-analysis of the rate and risk factors for post-transplant disease recurrence in children with steroid-resistant nephrotic syndrome","volume":"8","author":"Morello","year":"2023","journal-title":"Kidney International Reports"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD003594.pub7-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0022-3476(05)82020-7","article-title":"Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology","volume":"125","author":"Niaudet","year":"1994","journal-title":"Journal of Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00467-018-3994-3","article-title":"Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings [Erratum in: Pediatr Nephrol. 2019 Mar;34(3):539; PMID: 30443740]","volume":"33","author":"Pelletier","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0160|cit160","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0161|cit161","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00467-013-2736-9","article-title":"Predictors of remission and relapse in idiopathic nephrotic syndrome: a prospective cohort study","volume":"29","author":"Sureshkumar","year":"2014","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1757940","DOI":"10.1155\/2017\/1757940","article-title":"Pulsed vincristine therapy in steroid-resistant nephrotic syndrome","volume":"2017","author":"Thalgahagoda","year":"2017","journal-title":"BioMed Research International"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12939-023-01864-z","article-title":"Prioritising Cochrane reviews to be updated with health equity focus","volume":"22","author":"Tomlinson","year":"2023","journal-title":"International Journal for Equity in Health"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub7-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2215\/CJN.06260614","article-title":"Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort","volume":"10","author":"Trautmann","year":"2015","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"3055\u201365","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fped.2018.00200","article-title":"Exploring the clinical and genetic spectrum of steroid-resistant nephrotic syndrome: the PodoNet Registry","volume":"6","author":"Trautmann","year":"2018","journal-title":"Frontiers in Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/ndt\/gfad128","article-title":"Why FSGS keeps being presented as a disease although it is not","volume":"38","author":"Tullus","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub7-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s004670050216","article-title":"Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease","volume":"10","author":"Tune","year":"1996","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub7-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"e13955","DOI":"10.1111\/petr.13955","article-title":"Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis\/steroid-resistant nephrotic syndrome","volume":"25","author":"Weber","year":"2021","journal-title":"Pediatric Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub7-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1440-1754.2007.01077.x","article-title":"Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study","volume":"43","author":"Wong","year":"2007","journal-title":"Journal of Paediatrics & Child Health"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00467-024-06422-5","article-title":"Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study","volume":"39","author":"Yokota","year":"2024","journal-title":"Pediatric Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Habashy","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub7-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00467-003-1207-0","article-title":"Interventions for steroid-resistant nephrotic syndrome: a systematic review","volume":"18","author":"Habashy","year":"2003","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub7-BIB0176|cit176","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub2","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Habashy","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub7-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub3","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Habashy","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub7-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub4","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Hodson","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub7-BIB0179|cit179","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub5","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Hodson","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub7-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub6","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Liu","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:06:08Z","timestamp":1788573968000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003594.pub7"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":180,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003594.pub7","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}